Authors: Nigel T Brockton, Linda S Cook, Anthony M Magliocco, Carrie S Shemanko, Hans J Vogel, Momtafin Khan, Karen A Kopciuk
Journal: International Journal of Environmental Research and Public Health
Publisher: MDPI
Publication Date: 2025/2/8
Background
In the LUMINOSITY study (NCT03539536), telisotuzumab vedotin, a c-Met (MET) protein-directed ADC, showed promising antitumor activity in pts with NSQ NSCLC with c-Met OE. We present results from the METRIX study, which evaluated RW prevalence of c-Met OE across geographies, pt ethnicities, and pt characteristics, and associations with key oncogenic driver mutations. The reproducibility of c-Met testing in the RW setting and concordance between local/central labs was assessed.